-
The FDA has approved, by priority review, the first drug to help manage patients with phenylketonuria (PKU).
-
Absent or low testosterone levels in men appear to have a pathogenic role in the development of cardiovascular disease resulting in increased cardiovascular and all-cause mortality and are not simply "markers" for illness or wellness.
-
Patients with mild-to-moderate obstructive sleep apnea (OSA) who were treated with Continuous Positive Airway Pressure (CPAP) experienced an absolute risk reduction in cardiovascular risk compared with those who were not treated.
-
The number, type, and severity of comorbidities are important determinants of diabetes self-care.
-
The FDA has approved a non-halogenated nasal steroid for use in pediatric patients aged 6 to 12 years and adults. Ciclesonide is a prodrug that was previously approved for adults and adolescents but was not marketed. It's to be marketed by Nycomed US Inc. as Omnaris.
-
Serum analysis of 45 subjects for antibodies and humoral immunity over a median of 15 years showed antiviral responses ranging from 11-19 years for tetanus-diphtheria, 50 years for varicella-zoster, and up to 200 years for measles and mumps.
-
FDA warnings for existing drugs dominate pharmaceutical news this month.
-
12-lead ECG obtained from a 50-year old African American man with hypertension and chest pain.
-
-
When whole grain cereal (WGC) is consumed regularly, there is a lower risk of developing heart failure (HF). This association is likely to be linked to the beneficial effects of WGC on risk factors (ie, hypertension, obesity, hyperlipidemia) rather than HF itself.